Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma.

Ishan Mehta, Alimu Dayimu,Satish Kumar, Clare Boobier,Olabode Oladipo, David Burke, Anna Olson-Brown, Pembe Yesildag,Jenny Nobes, Stephanie Brown,Catherine Booth,Matthew Wheater, Daniel Muller, Vanessa Fountain, Lucy Ford,Ruth Board, Luke McGurk,Sophie Twelves,Nikos Demiris,Pippa Corrie

European journal of cancer (Oxford, England : 1990)（2023）

引用 0|浏览7

暂无评分

摘要

Q6W is an appropriate option for administering pembrolizumab, given the opportunity to reduce the health service resource burden.

查看译文

关键词

Pembrolizumab, Melanoma, Scheduling, Toxicity, Efficacy, Real-world data

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要